NovaBridge Biosciences (NBP) - Net Assets
Based on the latest financial reports, NovaBridge Biosciences (NBP) has net assets worth $1.84 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.97 Billion) and total liabilities ($131.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NovaBridge Biosciences (NBP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.84 Billion |
| % of Total Assets | 93.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | -96.43% |
| 10-Year Change | N/A |
| Growth Volatility | 25.93 |
NovaBridge Biosciences - Net Assets Trend (2017–2024)
This chart illustrates how NovaBridge Biosciences's net assets have evolved over time, based on quarterly financial data. Also explore NovaBridge Biosciences total assets for the complete picture of this company's asset base.
Annual Net Assets for NovaBridge Biosciences (2017–2024)
The table below shows the annual net assets of NovaBridge Biosciences from 2017 to 2024. For live valuation and market cap data, see NBP market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $201.16 Million | -88.29% |
| 2023-12-31 | $1.72 Billion | -42.89% |
| 2022-12-31 | $3.01 Billion | -34.43% |
| 2021-12-31 | $4.59 Billion | -18.47% |
| 2020-12-31 | $5.63 Billion | +376.56% |
| 2019-12-31 | $-2.03 Billion | -113.03% |
| 2018-12-31 | $-955.10 Million | -218.59% |
| 2017-12-31 | $-299.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NovaBridge Biosciences's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 92817900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.01% |
| Other Comprehensive Income | $33.38 Million | 16.60% |
| Other Components | $1.45 Billion | 722.71% |
| Total Equity | $201.16 Million | 100.00% |
NovaBridge Biosciences Competitors by Market Cap
The table below lists competitors of NovaBridge Biosciences ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FutureChem Co.Ltd
KQ:220100
|
$274.64 Million |
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
$274.88 Million |
|
Polyplex (Thailand) Public Company Limited
BK:PTL
|
$274.91 Million |
|
OVB Holding AG
XETRA:O4B
|
$275.06 Million |
|
Anhui Huaqi Environmental Protection Technology Co. Ltd.
SHE:300929
|
$274.37 Million |
|
Namchow Chemical Industrial Co Ltd
TW:1702
|
$274.35 Million |
|
Mangalam Cement Limited
NSE:MANGLMCEM
|
$274.33 Million |
|
Bourrelier Group SA
PA:ALBOU
|
$274.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NovaBridge Biosciences's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,718,156,000 to 201,160,000, a change of -1,516,996,000 (-88.3%).
- Net loss of 162,257,000 reduced equity.
- Share repurchases of 335,000 reduced equity.
- Other comprehensive income decreased equity by 6,387,000.
- Other factors decreased equity by 1,348,017,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-162.26 Million | -80.66% |
| Share Repurchases | $335.00K | -0.17% |
| Other Comprehensive Income | $-6.39 Million | -3.18% |
| Other Changes | $-1.35 Billion | -670.12% |
| Total Change | $- | -88.29% |
Book Value vs Market Value Analysis
This analysis compares NovaBridge Biosciences's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-5.15 | $2.38 | x |
| 2018-12-31 | $-16.42 | $2.38 | x |
| 2019-12-31 | $-34.98 | $2.38 | x |
| 2020-12-31 | $82.31 | $2.38 | x |
| 2021-12-31 | $60.40 | $2.38 | x |
| 2022-12-31 | $36.46 | $2.38 | x |
| 2023-12-31 | $20.64 | $2.38 | x |
| 2024-12-31 | $2.48 | $2.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NovaBridge Biosciences utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-80.66%) is below the historical average (-36.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -2580.82% | 0.01x | 0.00x | $-268.26 Million |
| 2018 | 0.00% | -749.02% | 0.02x | 0.00x | $-307.32 Million |
| 2019 | 0.00% | -4950.00% | 0.02x | 0.00x | $-1.28 Billion |
| 2020 | 8.37% | 30.53% | 0.24x | 1.13x | $-91.80 Million |
| 2021 | -50.82% | -2648.70% | 0.02x | 1.23x | $-2.79 Billion |
| 2022 | -83.35% | 0.00% | 0.00x | 1.35x | $-2.81 Billion |
| 2023 | -85.31% | -32674.02% | 0.00x | 1.52x | $-1.64 Billion |
| 2024 | -80.66% | 0.00% | 0.00x | 1.06x | $-182.37 Million |
Industry Comparison
This section compares NovaBridge Biosciences's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NovaBridge Biosciences (NBP) | $1.84 Billion | 0.00% | 0.07x | $274.39 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more